132 related articles for article (PubMed ID: 18614133)
21. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
Cho M; Barbazetto IA; Freund KB
Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
[TBL] [Abstract][Full Text] [Related]
22. Extensive submacular haemorrhage in polypoidal choroidal vasculopathy managed by sequential gas displacement and photodynamic therapy: a pilot study of one-year follow up.
Chan WM; Liu DT; Lai TY; Li H; Tong JP; Lam DS
Clin Exp Ophthalmol; 2005 Dec; 33(6):611-8. PubMed ID: 16402954
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
24. Role of photodynamic therapy in polypoidal choroidal vasculopathy.
Akaza E; Yuzawa M; Matsumoto Y; Kashiwakura S; Fujita K; Mori R
Jpn J Ophthalmol; 2007; 51(4):270-7. PubMed ID: 17660987
[TBL] [Abstract][Full Text] [Related]
25. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Tano Y
Br J Ophthalmol; 2008 Jul; 92(7):936-40. PubMed ID: 18577645
[TBL] [Abstract][Full Text] [Related]
26. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
[TBL] [Abstract][Full Text] [Related]
27. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
28. Reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
Chhablani J
Am J Ophthalmol; 2010 Sep; 150(3):443-4; author reply 444. PubMed ID: 20728684
[No Abstract] [Full Text] [Related]
29. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
30. Responses to photodynamic therapy in patients with polypoidal choroidal vasculopathy consisting of polyps resembling grape clusters.
Lee WK; Kim KS; Kim W; Lee SB; Jeon S
Am J Ophthalmol; 2012 Aug; 154(2):355-365.e1. PubMed ID: 22541658
[TBL] [Abstract][Full Text] [Related]
31. [Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy: long-term results].
Saito M; Nagayama D; Iida T
Nippon Ganka Gakkai Zasshi; 2009 Aug; 113(8):792-9. PubMed ID: 19715154
[TBL] [Abstract][Full Text] [Related]
32. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula.
Lee SC; Seong YS; Kim SS; Koh HJ; Kwon OW
Ophthalmologica; 2004; 218(3):193-201. PubMed ID: 15103216
[TBL] [Abstract][Full Text] [Related]
33. Role of photodynamic therapy in polypoidal choroidal vasculopathy.
Hussain N; Hussain A; Natarajan S
Indian J Ophthalmol; 2005 Jun; 53(2):101-4. PubMed ID: 15976464
[TBL] [Abstract][Full Text] [Related]
34. Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy.
Mauget-Faÿsse M; Quaranta-El Maftouhi M; De La Marnièrre E; Leys A
Eur J Ophthalmol; 2006; 16(5):695-704. PubMed ID: 17061220
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
36. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
37. Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy.
Yamashiro K; Tsujikawa A; Nishida A; Mandai M; Kurimoto Y
Jpn J Ophthalmol; 2008; 52(6):457-462. PubMed ID: 19089566
[TBL] [Abstract][Full Text] [Related]
38. [Photodynamic therapy for polypoidal choroidal vasculopathy].
You J; Guo X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):899-902. PubMed ID: 21946209
[TBL] [Abstract][Full Text] [Related]
39. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.
Mori R; Yuzawa M; Lee Z; Haruyama M; Akaza E
Graefes Arch Clin Exp Ophthalmol; 2010 Sep; 248(9):1233-9. PubMed ID: 20352440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
